Table 2. Cycle threshold values (Ct) and comparative statistics of studied miRNAs between the BC patients group and control group.

miRNA	BCCt mean ± SD	Control Ct mean ± SD	Cel-miR-39 normalization				miR-222-3p normalization
			BC ΔCt mean ± SE	Control ΔCt mean ± SE	ΔΔCt (95% CI), log2 fold change	P value	BC ΔCt mean ± SE	Control ΔCt mean ± SE	ΔΔCt (95% CI), log2 fold change	P value
miR-145-5p	29.52 ± 1.52	32.41 ± 1.19	−10.94 ± 0.21	−13.30 ± 0.16	2.36 (1.84; 2.88)	9.2e−10	−0.84 ± 0.11	−2.22 ± 0.12	1.38 (1.06; 1.72)	6.5e−12
miR-16-5p	22.72 ± 1.70	23.94 ± 1.46	−4.14 ± 0.20	−4.83 ± 0.18	0.69 (0.15; 1.23)	0.020	5.96 ± 0.15	6.25 ± 0.14	−0.29(−0.69; 0.12)	0.081
miR-191-5p	26.76 ± 1.76	29.17 ± 1.17	−8.18 ± 0.26	−10.05 ± 0.14	1.87 (1.28; 2.46)	2.3e−08	1.92 ± 0.08	1.02 ± 0.09	0.89 (0.66; 1.13)	3.7e−10
miR-21-5p	26.24 ± 1.84	28.13 ± 1.10	−7.66 ± 0.18	−9.02 ± 0.14	1.35 (0.89; 1.82)	3.2e−07	2.44 ± 1.17	2.06 ± 0.09	0.38 (−0.04; 0.76)	0.0034
miR-210-3p	32.31 ± 1.38	33.53 ± 1.09	−13.73 ± 0.17	−14.42 ± 0.15	0.69 (0.24; 1.14)	0.0023	−3.63 ± 0.15	−3.35 ± 0.11	−0.29(−0.65; 0.08)	0.100
miR-29c-3p	33.87 ± 1.81	35.38 ± 0.96	−15.29 ± 0.22	−16.27 ± 0.10	0.98 (0.49; 1.47)	0.0002	−5.19 ± 0.10	−5.19 ± 0.07	0.01 (−0.24; 0.25)	0.845
miR-222-3p	28.68 ± 1.52	30.19 ± 0.84	−10.10 ± 0.20	−11.08 ± 0.08	0.98 (0.53; 1.42)	0.0006	–	–	–	–
cel-miR-39	18.58 ± 1.10	19.11 ± 0.67	–	–	–	–	−10.10 ± 0.20	−11.08 ± 0.08	−0.98 (−1.42; −0.53)	0.0002